CureVac Doses First Patient In Phase 1 Study Of Cancer Vaccine Candidate For Surgically Resected Glioblastoma
Portfolio Pulse from Benzinga Newsdesk
CureVac has initiated a Phase 1 clinical trial for its cancer vaccine candidate, CV8102, targeting surgically resected glioblastoma. The first patient has been dosed in the study.
June 20, 2023 | 11:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CureVac has dosed the first patient in a Phase 1 study of its cancer vaccine candidate, CV8102, for surgically resected glioblastoma.
The initiation of the Phase 1 clinical trial for CV8102 is a positive development for CureVac, as it represents progress in their pipeline. This news may increase investor confidence in the company's ability to develop and advance new treatments, potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100